Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | OXER1 | Q8TDS5 | 9/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17345582 | 0.90 | KMT2A (0.47) | KMT2AMEN1OXER1LTB4RLTB4R2 | |
| SCHEMBL17341979 | 0.89 | ALDH1A1 (0.38) | KMT2AMEN1OXER1LTB4RLTB4R2 | |
| SCHEMBL17345615 | 0.87 | OXER1 (0.41) | KMT2AMEN1OXER1LTB4RLTB4R2 | |
| SCHEMBL17345612 | 0.81 | LTB4R (0.43) | OXER1LTB4RLTB4R2HDAC3HDAC4 | |
| SCHEMBL17341981 | 0.80 | KMT2A (0.48) | KMT2AMEN1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL17345613 | 0.79 | GABRA1 (0.47) | KMT2AMEN1OXER1LTB4RLTB4R2 | |
| SCHEMBL17345609 | 0.78 | OXER1 (0.40) | KMT2AMEN1OXER1LTB4RLTB4R2 | |
| SCHEMBL17341966 | 0.78 | ALDH1A1 (0.38) | KMT2AMEN1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL17341965 | 0.78 | KMT2A (0.49) | KMT2AMEN1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL8936810 | 0.74 | L3MBTL1 (0.51) | KMT2AMEN1LTB4RLTB4R2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377716-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9790186-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377716-B2 | Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection | FABP2, LRBA, VIP | KMT2A 4736/4885MEN1 3773/4885OXER1 1107/4885 |
| US-20150361045-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | KMT2A 4736/4885MEN1 3773/4885OXER1 1107/4885 |
| US-20180029990-A1 | COMPOSITION AND METHOD FOR PREVENTION, MITIGATION OR TREATMENT OF AN ENTEROPATHOGENIC BACTERIAL INFECTION | FABP2, LRBA, VIP | KMT2A 4736/4885MEN1 3773/4885OXER1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.